41.235 articles found

Treatment options in Parkinson's disease.

Beizer JL.

Am Pharm · 1995-01-01

DOI: 10.1016/s0160-3450(16)33862-4PMID: 7887371

Thalamotomy for movement disorders.

Burchiel KJ.

Neurosurg Clin N Am · 1995-01-01

DOI: 10.1016/s1042-3680(18)30477-7PMID: 7696875

Bromocriptine and psychosis: a literature review.

Boyd A.

Psychiatr Q · 1995-01-01

DOI: 10.1007/bf02238717PMID: 7701022

Viruses, schizophrenia, and bipolar disorder.

Yolken RH, Torrey EF.

Clin Microbiol Rev · 1995-01-01

DOI: 10.1128/cmr.8.1.131PMID: 7704891

[The painful body of the psychotic. A balance between psychiatric symptoms and somatic diseases in somatic patients].

Blanquer A, Veyrat JG.

Ann Med Psychol (Paris) · 1995-01-01

PMID: 7710187

Extrapyramidal symptoms associated with calcium-channel blockers.

Daniel JR, Mauro VF.

Ann Pharmacother · 1995-01-01

DOI: 10.1177/106002809502900113PMID: 7711350

The role of the basal ganglia in nociception and pain.

Chudler EH, Dong WK.

Pain · 1995-01-01

DOI: 10.1016/0304-3959(94)00172-bPMID: 7715939

Protein redistribution to improve quality of life for those with Parkinson's disease: a review

Burk-Shull KA.

Topics in clinical nutrition · 1994-12-01

The 1993 Upjohn Award Lecture. Quinolinic acid induced brain neurotransmitter deficits: modulation by endogenous excitotoxin antagonists.

Jhamandas KH, Boegman RJ, Beninger RJ.

Can J Physiol Pharmacol · 1994-12-01

DOI: 10.1139/y94-213PMID: 7736338

[Superoxide formation and lipid peroxidation by the mitochondrial electron-transfer chain].

Takeshige K.

Rinsho Shinkeigaku · 1994-12-01

PMID: 7774132

Pineal-hypothalamic tract mediation of picotesla magnetic fields in the treatment of neurological disorders.

Jacobson JI.

Panminerva Med · 1994-12-01

PMID: 7603740

Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.

Youdim MB, Finberg JP.

Clin Pharmacol Ther · 1994-12-01

DOI: 10.1038/clpt.1994.202PMID: 7995014